Effects of naltrexone on smoking cessation outcomes and weight gain in nicotine-dependent men and women

Journal of Clinical Psychopharmacology

Volumn 32, Issue 5, 2012, Pages 630-636

  King, Andrea C ^a   Cao, Dingcai ^a   O'Malley, Stephanie S ^b   Kranzler, Henry R ^c   Cai, Xiaochen ^a   Dewit, Harriet ^a   Matthews, Alicia K ^d   Stachoviak, Ryan J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

naltrexone; nicotine dependence; quit rates; sex differences; smoking cessation; weight gain

Indexed keywords

NALTREXONE;

ADULT; ARTICLE; BEHAVIOR THERAPY; COGNITIVE THERAPY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COUNSELING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SIDE EFFECT; SMOKING CESSATION; TOBACCO DEPENDENCE; TREATMENT OUTCOME; WEIGHT GAIN;

ADMINISTRATION, ORAL; ADULT; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; SEX FACTORS; SMOKING CESSATION; TIME FACTORS; TOBACCO USE CESSATION PRODUCTS; TOBACCO USE DISORDER; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 84865861685     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3182676956     Document Type: Article

References (49)

1. Cigarette smoking among adults and trends in smoking cessationVUnited States, 2008. MMWR Morb Mortal Wkly Rep. 2009;58(44):1227-1232.
2. Annual smoking-attributable mortality, years of potential life lost, and economic costsVUnited States, 1995-1999. MMWR Morb Mortal Wkly Rep. 2002;51(14):300-303.
3. Fiore MC, Jaén CR, Baker TB, et al. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD: US Department of Health and Human Services, Public Health Service; 2008.
4. Berridge KC, Ho CY, Richard JM, et al. The tempted brain eats: pleasure and desire circuits in obesity and eating disorders. Brain Res. 2010;1350:43-64.
5. King A, de Wit H, Riley RC, et al. Efficacy of naltrexone in smoking cessation: a preliminary study and an examination of sex differences. Nicotine Tob Res. 2006;8(5):671-682.
6. O'Malley SS, Cooney JL, Krishnan-Sarin S, et al. A controlled trial of naltrexone augmentation of nicotine replacement therapy for smoking cessation. Arch Intern Med. 2006;166(6):667-674.
7. King A, Torello R, Krishnan-Sarin S, et al. Naltrexone in smoking cessation: a review of the literature and future directions. In: Dean R, Bilsky E, Negus S, eds. Opiate Receptors and Antagonists. Belmont, MA: Springer; 2009:307-324.
8. Fiore MC, Jorenby DE, Baker TB, et al. Tobacco dependence and the nicotine patch. Clinical guidelines for effective use. JAMA. 1992;268(19):2687-2694.
9. Wong GY, Wolter TD, Croghan GA, et al. A randomized trial of naltrexone for smoking cessation. Addiction. 1999;94(8):1227-1237.
10. Toll BA, White M, Wu R, et al. Low-dose naltrexone augmentation of nicotine replacement for smoking cessation with reduced weight gain: a randomized trial. Drug Alcohol Depend. 2010;111(3):200-206.
11. David SP, Lancaster T, Stead LF, et al. Opioid antagonists for smoking cessation (review). Cochrane Database Syst Rev. 2009;(4):CD003086.
12. Covey LS, Glassman AH, Stetner F. Naltrexone effects on short-term and long-term smoking cessation. J Addict Dis. 1999;18(1):31-40.
13. Byars JA, Frost-Pineda K, Jacobs WS, et al. Naltrexone augments the effects of nicotine replacement therapy in female smokers. J Addict Dis. 2005;24(2):49-60.
14. Munafo M, Bradburn M, Bowes L, et al. Are there sex differences in transdermal nicotine replacement therapy patch efficacy? A meta-analysis. Nicotine Tob Res. 2004;6(5):769-776.
15. Perkins KA, Scott J. Sex differences in long-term smoking cessation rates due to nicotine patch. Nicotine Tob Res. 2008;10(7):1245-1250.
16. Smith YR, Stohler CS, Nichols TE, et al. Pronociceptive and antinociceptive effects of estradiol through endogenous opioid neurotransmission in women. J Neurosci. 2006;26(21): 5777-5785.
17. Zubieta JK, Smith YR, Bueller JA, et al. mu-Opioid receptorYmediated antinociceptive responses differ in men and women. J Neurosci. 2002;22(12):5100-5107.
18. Roche DJ, Childs E, Epstein AM, et al. Acute HPA axis response to naltrexone differs in female vs. male smokers. Psychoneuroendocrinology. 2010;35(4):596-606.
19. Epperson CN, Toll B, Wu R, et al. Exploring the impact of gender and reproductive status on outcomes in a randomized clinical trial of naltrexone augmentation of nicotine patch. Drug Alcohol Depend. 2010;112(1-2):1-8.
20. Jo YH, Talmage DA, Role LW. Nicotinic receptorYmediated effects on appetite and food intake. J Neurobiol. 2002;53(4):618-632.
21. Klesges RC, DeBon M, Vander Weg MW, et al. Efficacy of a tailored tobacco control program on long-term use in a population of U.S. military troops. J Consult Clin Psychol. 2006;74(2): 295-306.
22. Sanchez-Johnsen LA, Carpentier MR, King AC. Race and sex associations to weight concerns among urban African American and Caucasian smokers. Addict Behav. 2011;36(1-2):14-17.
23. Mizes JS, Sloan DM, Segraves K, et al. The influence of weight-related variables on smoking cessation. Behav Ther. 1998;29(3):371-385.
24. Pecina S, Smith KS. Hedonic and motivational roles of opioids in food reward: implications for overeating disorders. Pharmacol Biochem Behav. 2010;97(1):34-46.
25. Yeomans MR, Gray RW. Opioid peptides and the control of human ingestive behaviour. Neurosci Biobehav Rev. 2002;26(6):713-728.
26. Weerts EM, Kim YK, Wand GS, et al. Differences in delta-and mu-opioid receptor blockade measured by positron emission tomography in naltrexone-treated recently abstinent alcohol-dependent subjects. Neuropsychopharmacology. 2008;33(3):653-665.
27. Krishnan-Sarin S, Rosen MI, O'Malley SS. Naloxone challenge in smokers. Preliminary evidence of an opioid component in nicotine dependence. Arch Gen Psychiatry. 1999;56(7):663-668.
28. Cummings KM, Giovino G, Jaen CR, et al. Reports of smoking withdrawal symptoms over a 21 day period of abstinence. Addict Behav. 1985;10(4):373-381.
29. King AC, Meyer PJ. Naltrexone alteration of acute smoking response in nicotine-dependent subjects. Pharmacol Biochem Behav. 2000;66(3):563-572.
30. King AC, Cao D, Southard CC, et al. Racial differences in eligibility and enrollment in a smoking cessation clinical trial. Health Psychol. 2011;30(1):40-48.
31. Heatherton TF, Kozlowski LT, Frecker RC, et al. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict. 1991;86(9):1119-1127.
32. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders, Research Version, Non-patient Edition. New York, NY: Biometrics Research, New York State Psychiatric Institute; 2002.
33. Pierce JP, Gilpin EA. Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation. JAMA. 2002;288(10):1260-1264.
34. King A, Sanchez-Johnsen L, Van Orman S, et al. A pilot community-based intensive smoking cessation intervention in African Americans: feasibility, acceptability and early outcome indicators. J Natl Med Assoc. 2008;100(2):208-217.
35. Sobell LC, Sobell MB. Timeline Follow Back: A Calendar Method for Assessing Alcohol and Drug Use (User's Guide). Toronto, Canada: Addiction Research Foundation; 1996.
36. Cox LS, Tiffany ST, Christen AG. Evaluation of the brief questionnaire of smoking urges (QSU-brief ) in laboratory and clinical settings. Nicotine Tob Res. 2001;3(1):7-16.
37. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4(6):561-671.
38. Hughes JR, Keely JP, Niaura RS, et al. Measures of abstinence in clinical trials: issues and recommendations. Nicotine Tob Res. 2003;5(1):13-25.
39. Javors MA, Hatch JP, Lamb RJ. Cut-off levels for breath carbon monoxide as a marker for cigarette smoking. Addiction. 2005;100(2):159-167.
40. Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics. 1988;44(4):1049-1060.
41. Stewart ST, Cutler DM, Rosen AB. Forecasting the effects of obesity and smoking on U.S. life expectancy. N Engl J Med. 2009;361(23):2252-2260.
42. Stein CJ, Colditz GA. The epidemic of obesity. J Clin Endocrinol Metab. 2004;89(6):2522-2525.
43. Drewnowski A, Krahn DD, Demitrack MA, et al. Naloxone, an opiate blocker, reduces the consumption of sweet high-fat foods in obese and lean female binge eaters. Am J Clin Nutr. 1995;61(6):1206-1212.
44. Kranzler HR, Tennen H, Armeli S, et al. Targeted naltrexone for problem drinkers. J Clin Psychopharmacol. 2009;29(4):350-357.
45. Greenfield SF, Pettinati HM, O'Malley S, et al. Gender differences in alcohol treatment: an analysis of outcome from the COMBINE study. Alcohol Clin Exp Res. 2010;34(10):1803-1812.
46. Urban NB, Kegeles LS, Slifstein M, et al. Sex differences in striatal dopamine release in young adults after oral alcohol challenge: a positron emission tomography imaging study with [11C]raclopride. Biol Psychiatry. 2010;68(8):689-696.
47. Rukstalis M, Jepson C, Strasser A, et al. Naltrexone reduces the relative reinforcing value of nicotine in a cigarette smoking choice paradigm. Psychopharmacology (Berl). 2005;180(1):41-48.
48. Smith YR, Zubieta JK, del Carmen MG, et al. Brain opioid receptor measurements by positron emission tomography in normal cycling women: relationship to luteinizing hormone pulsatility and gonadal steroid hormones. J Clin Endocrinol Metab. 1998;83(12):4498-4505.
49. Perkins KA. Smoking cessation in women. Special considerations. CNS Drugs. 2001;15(5):391-411.